{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T00:09:37Z","timestamp":1795133377490,"version":"4.10.3"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>\n                      Cyclin-dependent kinase (CDK) 4 and 6 inhibitors (CDK4\/6i) combined with endocrine therapy are widely used in hormone receptor (HR)\u2013positive,\n                      <jats:italic>ERBB2<\/jats:italic>\n                      -negative advanced breast cancer (ABC). The SONIA trial evaluates the optimal timing of CDK4\/6i administration, either in first-line or second-line setting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine whether first-line CDK4\/6i use is superior to second-line use in terms of overall survival (OS) and to provide an updated analysis of the primary end point of progression-free survival (PFS) after 2 lines of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>\n                      The phase 3 SONIA randomized clinical trial is a multicenter trial in the Netherlands. Patients with HR-positive,\n                      <jats:italic>ERBB2<\/jats:italic>\n                      -negative ABC who did not receive prior treatment for ABC were randomized 1:1 to receive CDK4\/6i added to first-line or second-line endocrine therapy. Patients were enrolled between November 23, 2017, and September 1, 2021. Data cutoff for this prespecified updated analysis was September 1, 2024. Data were analyzed from February to May 2025.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Aromatase inhibitor plus CDK4\/6i as first-line treatment followed by fulvestrant as second-line treatment (CDK4\/6i first-line group) vs aromatase inhibitor as first-line treatment followed by fulvestrant plus CDK4\/6i as second-line treatment (CDK4\/6i second-line group).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary end point was PFS after 2 lines of therapy. OS was a key secondary end point, with a prespecified analysis when all patients had 3 or more years of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 1050 enrolled patients, the median (IQR) age was 64 (16) years. A total of 524 were randomized to the CDK4\/6i first-line group and 526 patients to the CDK4\/6i second-line group. At a median follow-up of 58.5 months (95% CI, 57.0-60.9), 606 deaths (57.7%) had occurred. The median OS was 47.9 months (95% CI, 44.0-54.3) with first-line CDK4\/6i and 48.1 months (95% CI, 44.7-52.0) with second-line CDK4\/6i (hazard ratio [HR], 0.91; 95% CI, 0.77-1.07;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.24). A post hoc subgroup analysis suggested an OS benefit with first-line use in premenopausal patients (HR, 0.53; 95% CI, 0.32-0.87) but not in postmenopausal patients (HR, 1.00; 95% CI, 0.84-1.19;\n                      <jats:italic>P<\/jats:italic>\n                      for interaction\u2009=\u2009.01). Among patients who discontinued second-line treatment, 257 of 303 in the first-line group (84.8%) and 303 of 360 in the second-line group (84.2%) received subsequent anticancer therapy, with similar treatment patterns. First-line CDK4\/6i use was associated with more grade 3 or higher adverse events than second-line use (3400 vs 2242, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this phase 3 randomized clinical trial, first-line CDK4\/6i use did not improve OS compared with second-line use but did increase treatment-related toxic effects. Post hoc analysis suggests an OS benefit with first-line use in premenopausal patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03425838\">NCT03425838<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.6585","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:00:42Z","timestamp":1771516842000},"page":"375","source":"Crossref","is-referenced-by-count":20,"title":["Overall Survival With First-Line vs Second-Line CDK4\/6 Inhibitor Use in Advanced Breast Cancer"],"prefix":"10.1001","volume":"12","author":[{"given":"Noor","family":"Wortelboer","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek","family":"van Ommen-Nijhof","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge R.","family":"Konings","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"van der Noort","sequence":"additional","affiliation":[{"name":"Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"van den Pol","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Guerrero P\u00e1ez","sequence":"additional","affiliation":[{"name":"Dutch Breast Cancer Society, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra D.","family":"Bakker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Zaans Medical Centre, Zaandam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd","family":"Hovenga","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Nij Smellinghe Hospital, Drachten, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex L. T.","family":"Imholz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Deventer Hospital, Deventer, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne J. L.","family":"Kamm","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Maas Hospital Pantein, Boxmeer, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lobke","family":"van Leeuwen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Diakonessenhuis, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia A.","family":"Luykx-de Bakker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tergooi Medical Centre, Hilversum, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M. P. W.","family":"Mandigers","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M. G. H.","family":"van Riel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"Tol","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jeroen Bosch Hospital, \u2019s-Hertogenbosch, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes J.","family":"van de Wouw","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Viecuri Medical Center, Venray, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia M.","family":"Wilting","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Elise","family":"van Leeuwen-Stok","sequence":"additional","affiliation":[{"name":"Dutch Breast Cancer Research Group, BOOG Study Center, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe S.","family":"Sonke","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Netherlands Cancer Institute and University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"20","key":"coi250089r1","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer.","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"18","key":"coi250089r2","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer.","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"32","key":"coi250089r3","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer.","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi250089r4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"coi250089r5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"issue":"24","key":"coi250089r6","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3.","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"25","key":"coi250089r7","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy.","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi250089r8","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer.","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"coi250089r9","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer.","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"coi250089r10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer.","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"coi250089r11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial.","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"issue":"8","key":"coi250089r12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"coi250089r13","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall survival with palbociclib plus letrozole in advanced breast cancer.","volume":"42","author":"Slamon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"20","key":"coi250089r14","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer.","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"coi250089r15","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/s41571-023-00805-7","article-title":"Problematic crossovers in cancer drug trials.","volume":"20","author":"Gyawali","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"coi250089r16","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"coi250089r17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN Guidelines\u00ae Insights: Breast Cancer, Version 4.2023.","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"8042","key":"coi250089r18","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08035-2","article-title":"Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer.","volume":"636","author":"Sonke","year":"2024","journal-title":"Nature"},{"key":"coi250089r19","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf334","article-title":"Health-related quality of life with first- vs second-line CDK4\/6 inhibitor use in advanced breast cancer: results from the SONIA trial.","author":"Wortelboer","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"coi250089r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.116051","article-title":"Health economic outcomes and costs of CDK4\/6 inhibitor use in first- versus second-line for advanced breast cancer: a cost-effectiveness analysis of the phase 3 SONIA trial.","volume":"231","author":"Wortelboer","year":"2025","journal-title":"Eur J Cancer"},{"issue":"1","key":"coi250089r21","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1186\/s12885-018-4978-1","article-title":"Selecting the optimal position of CDK4\/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.","volume":"18","author":"van Ommen-Nijhof","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"coi250089r22","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/S1470-2045(24)00451-0","article-title":"Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials.","volume":"26","author":"Gyawali","year":"2025","journal-title":"Lancet Oncol"},{"issue":"7","key":"coi250089r23","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1001\/jamaoncol.2025.1002","article-title":"Overall survival and quality-of-life superiority in modern phase 3 oncology trials: a meta-epidemiological analysis.","volume":"11","author":"Sherry","year":"2025","journal-title":"JAMA Oncol"},{"issue":"8","key":"coi250089r24","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.annonc.2025.04.006","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"coi250089r25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10549-013-2560-8","article-title":"Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry.","volume":"139","author":"Inwald","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"coi250089r26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13058-015-0618-8","article-title":"The molecular landscape of premenopausal breast cancer.","volume":"17","author":"Liao","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"4","key":"coi250089r27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s13058-014-0427-5","article-title":"Biology of breast cancer in young women.","volume":"16","author":"Azim","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"21","key":"coi250089r28","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1158\/1078-0432.CCR-18-0162","article-title":"Targeted therapy for premenopausal women with HR+, HER2- advanced breast cancer: focus on special considerations and latest advances.","volume":"24","author":"Bardia","year":"2018","journal-title":"Clin Cancer Res"},{"key":"coi250089r29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.breast.2022.01.014","article-title":"Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.","volume":"62","author":"Lee","year":"2022","journal-title":"Breast"},{"issue":"1","key":"coi250089r30","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41467-018-04129-4","article-title":"Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures.","volume":"9","author":"Kan","year":"2018","journal-title":"Nat Commun"},{"issue":"11","key":"coi250089r31","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1038\/s41591-025-03935-w","article-title":"Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial.","volume":"31","author":"Jongbloed","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"coi250089r32","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial.","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7","key":"coi250089r33","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.annonc.2025.03.023","article-title":"Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive\/HER2-negative BC patients: results from the multicenter PALMARES-2 study.","volume":"36","author":"Provenzano","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"coi250089r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104103","article-title":"Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2- metastatic breast cancer in the US real-world setting.","volume":"10","author":"Rugo","year":"2025","journal-title":"ESMO Open"},{"issue":"20","key":"coi250089r35","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer.","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"coi250089r36","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer.","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"coi250089r37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41523-024-00617-7","article-title":"CDK4\/6i-treated HR+\/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape.","volume":"10","author":"Chaudhary","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"32","key":"coi250089r38","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1200\/JCO.23.01423","article-title":"Progression-free survival should not be used as a primary end point for registration of anticancer drugs.","volume":"41","author":"Booth","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2845273\/jamaoncology_wortelboer_2026_oi_250089_1775759218.33833.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:00:26Z","timestamp":1776351626000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2845273"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.6585","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}